Thursday, October 15, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 29, 2026

If You Think President Donald Trump and the Fed Are Feuding Now, Wait Until the Effects of the Iran War Hit the Inflation Report

View original at nasdaq.com
If You Think President Donald Trump and the Fed Are Feuding Now, Wait Until the Effects of the Iran War Hit the Inflation Report Key Points Although Donald Trump nominated Jerome Powell to succeed Janet Yellen as Fed chair during his first term, he's been a vocal critic of Powell and the Fed since the start of his seco…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • If Trump wants someone easy on inflation, he got the wrong guy in Kevin Warsh

    60% confidence
  • The stock market entered 2026 at its second-priciest valuation in history according to S&P 500's Shiller Price-to-Earnings Ratio, dating back to January 1871

    60% confidence
  • Only 18.3% chance of a 25-basis-point rate cut for April FOMC meeting

    60% confidence
  • Economic data will guide the Federal Open Market Committee's monetary policy decisions

    60% confidence
  • Consumers are enduring the steepest one-month increase in fuel prices in three decades

    60% confidence
  • The trailing 12-month inflation rate is expected to jump from approximately 2.4% in February to an estimated 3.02% in March

    60% confidence
  • Federal funds target rate should be 1% or lower

    60% confidence
  • The inflationary effects of President Trump's tariffs are still working their way through the U.S. economy

    60% confidence
  • Approximately 20% of the world's liquid petroleum travels through the Strait of Hormuz daily

    60% confidence
  • 40.2% probability of a 25-basis-point rate hike for April FOMC meeting

    60% confidence
  • Stock Advisor's total average return is 884% compared to 179% for the S&P 500

    60% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com